About us
A unique biotechnology consulting firm
Biotherapy Partners was founded in 2019 by a group of senior experts in biotechnology and advanced therapy medicinal products development.
We are serving clients for projects on cell and gene therapies, recombinant proteins, live biotherapeutic products and training/coaching programs covering strategic advice and gap analysis, due diligence, training and operational support—from preclinical, CMC, translation, regulatory to project management. We have collaborated with companies mainly in the USA and Europe (France, Belgium, UK…).
Our vision
As a unique consulting firm, Biotherapy Partners envisions to support the complex approval process in the fast-changing biotechnologies field such as immunotherapy while prioritizing our client needs, above and beyond. We aim to be your business solution partners, bringing your innovative science ideas to the market access to the patients.
Biotherapy Partners is focused on science, driven by data and high standards for quality outputs.
Management Team
Alexis COLLETTE PhD, Partner & President
Translation, Analytical development, Bioanalysis
Alexis combines a strong expertise in development (CMC, bioanalysis mainly on biotech products) with a global business vision. He co-founded the CRO Texcell in 2003. He became Senior Director, Analytical Development at Stallergenes from 2014 to 2017. In 2019, he is cofounder and President of two consulting firms, Biotherapy Partners and Biotherapeutics CMC Solutions providing Translation, Project Management, Preclinical, CMC & management consulting services to more than 30 companies.
Alexis is alumnus of Ecole Normale Supérieure and holds a PhD in Immunology from Paris 6 University.
Olivier NEGRE Engineer, PhD, Partner
Preclinical Development
Olivier developed his expertise in preclinical research and translational science through more than 20 years of experience in biotherapies. He led the French Research & Development team of Bluebird bio for nine years. He transitioned to Bluebird bio Cambridge MA (USA) as Director Preclinical & Translational Research and was the head of the Stem Cell Group for five years. Overall, he contributed to the development of the first approved gene therapy for beta-thalassemia (Zynteglo), from preclinical studies to marketing authorization. Olivier developed his expertise in cellular immuno-oncology through autologous and allogeneic CAR-T projects.
Olivier holds a doctorate degree in cell and molecular biology. He is currently board member of the French Society and Gene and Cell Therapy, Co-President of the Gene and Cell Therapy Institute in Paris, member of the EuroGCT consortium, Head of R&D for Smart Immune and Partner at Biotherapy Partners.
Nicolas FERRY MD, PhD, Partner
Regulatory Expert
Nicolas is VP and Chief Development Officer at Horama. He served as a scientific director for gene and cell therapy at Servier Laboratories in Suresnes. He is also consulting since 2016. Nicolas has a strong background in basic and clinical research gained at the french National Health and Medical Research Institute (INSERM) where he was appointed as scientist form more that 25 years. He has a 6-year experience in the regulation of advanced therapies at the French (ANSM) and European (EMA) regulatory agencies. He has expertise in the CMC of such therapies, gained in an academic (Saint Louis Hospital) and industrial (Servier) environment.
Nicolas is physician and holds a PhD in endocrinology from Paris 6 University.
Hélène TREBEDEN, PharmD, PhD
Cell Therapy Process Expert
Hélène developed her expertise in Cell & Gene Therapy CMC through more than 20 years of experience in ATMPs. Initially, she worked at Pitié-Salpêtrière hospital (APHP) in the Biotherapy department in charge of the hematopoietic stem cell transplant processing. In 2014, she joined Dana Farber Cancer Institute (Boston) and worked for 5 years as technical Director of the Novel Cell therapy team in the Cell Manipulation Core Facility (Pr. Ritz). This unit was responsible for the development of novel cell manufacturing procedures and manufactured a variety of Cell and Gene Drug products: CAR-T cells, GMP IPS cell lines, CD34+ transduced cells, Mesenchymal Stromal Cells, Treg, NK cells…
Since September 2019, she is CMC Project leader for the allogenic CAR T program at SERVIER IRIS and also industrial Project leader for T2Evolve project; Innovative Medicine Initiative (IMI).
Hélène is a Pharm D (DES: Medical Biology) and earned a PhD in Immunology from Paris V University.
Join Biotherapy Partners
Biotherapy Partners is looking forward to work with new talents.
Send your resume at job@biotherapiespartbners.com or complete the form below.
